The Missing Link in Psychedelic Medicine Isn’t the Drug. It’s Everything Around It.
The psychedelic medicine market is projected to grow from $3.63 billion in 2024 to over $10 billion by 2032, according to SNS Insider. The FDA
The psychedelic medicine market is projected to grow from $3.63 billion in 2024 to over $10 billion by 2032, according to SNS Insider. The FDA
The race in psychedelic medicine has focused almost entirely on the molecule. Which compound wins approval first? Which trial reads out next? These are fair
Most conversations about depression and sleep stop at the obvious: people who are depressed often sleep badly. A 2026 study in Neuropsychopharmacology points somewhere deeper.
A major depressive episode can feel like standing in a room with no doors. Antidepressants may take four to six weeks to show results—and for
If you or someone you know is in crisis, confidential support is available 24/7 by calling or texting 988 (Suicide & Crisis Lifeline) or texting
On April 24, 2026, the FDA issued Commissioner’s National Priority Vouchers (CNPVs) to three companies developing psychedelic therapies for depression and PTSD. The move could
Forbes recently featured Nushama in an article exploring how psychedelic-assisted therapy could reshape the way we think about career mental health. Written by Bryan Robinson,
The executive order President Trump signed on April 18, 2026, directs federal agencies to speed up research and potential FDA approval for psychedelic compounds including
If you have tried antidepressants that did not work, or you would rather avoid medication altogether, you are not short on options. The harder question
For many people living with treatment-resistant depression (TRD), ketamine therapy works. Symptoms lift, sometimes within hours. The challenge is keeping them at bay. Standard IV
The psychedelic medicine market is projected to grow from $3.63 billion in 2024 to over $10 billion by 2032, according to SNS Insider. The FDA
The race in psychedelic medicine has focused almost entirely on the molecule. Which compound wins approval first? Which trial reads out next? These are fair
Most conversations about depression and sleep stop at the obvious: people who are depressed often sleep badly. A 2026 study in Neuropsychopharmacology points somewhere deeper.
A major depressive episode can feel like standing in a room with no doors. Antidepressants may take four to six weeks to show results—and for
If you or someone you know is in crisis, confidential support is available 24/7 by calling or texting 988 (Suicide & Crisis Lifeline) or texting
On April 24, 2026, the FDA issued Commissioner’s National Priority Vouchers (CNPVs) to three companies developing psychedelic therapies for depression and PTSD. The move could
Forbes recently featured Nushama in an article exploring how psychedelic-assisted therapy could reshape the way we think about career mental health. Written by Bryan Robinson,
The executive order President Trump signed on April 18, 2026, directs federal agencies to speed up research and potential FDA approval for psychedelic compounds including
If you have tried antidepressants that did not work, or you would rather avoid medication altogether, you are not short on options. The harder question
For many people living with treatment-resistant depression (TRD), ketamine therapy works. Symptoms lift, sometimes within hours. The challenge is keeping them at bay. Standard IV
